10061 Background: Limited clinical data on real-world practice patterns are available for care of pts with m/rSTS. This study evaluated drug tx patterns and outcomes in m/rSTS pts following failure of prior chemotherapy based on data from a U.S. referral academic cancer center. Methods: Data from medical records consented for research use were retrospectively reviewed at Dana-Farber Cancer Institute for pts with m/rSTS who were ≥18 years, commenced 2nd-line systemic therapy between 1/1/2000 and 2/4/2011, had confirmed disease progression on or after 1st-line therapy and had ≥3 months of observation. Pts were excluded if they had been diagnosed with gastrointestinal stromal tumor, bone sarcoma or dermatofibrosarcoma protuberans, or had ever been treated with pazopanib. Histologic subtype, tx type and duration, tx modifications (e.g., discontinuation) and reasons for modifications were examined. Overall survival, time to progression and clinician-assessed tumor response were collected. Results: Study pts had leiomyosarcoma (n=50), synovial cell sarcoma (n=7), liposarcoma (n=5) and other histologic subtypes (n=39). These 101 pts received an average 4 lines of tx (maximum=10 lines). Wide variations were noted in each line of tx (Table) with no consistent nor dominant regimens. Median 2nd-line tx duration was 4.1 months (95%CI 2.9-5.0). Among 98 pts who discontinued 2nd-line tx, 72 (73%) did so due to progressive disease, 10 due to “completion” of planned tx, and 6 to adverse events. Median progression-free survival from initiation of 2nd-line tx varied across regimens from 2.0 to 6.5 months (overall median 5.5 months). Conclusions: The wide variation in ≥2nd-line tx confirms there is no single “standard” of care for m/rSTS. The majority of pts discontinued 2nd-line tx due to progressive disease and often received additional lines of tx, indicating frequent physician and pt switching of tx. [Table: see text]